Review
Version 1
Preserved in Portico This version is not peer-reviewed
Purinergic Receptors: Elucidating the Role of These Immune Mediators in HIV-1 Fusion
Version 1
: Received: 24 January 2020 / Approved: 26 January 2020 / Online: 26 January 2020 (01:28:26 CET)
A peer-reviewed article of this Preprint also exists.
Freeman, T.L.; Swartz, T.H. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion. Viruses 2020, 12, 290. Freeman, T.L.; Swartz, T.H. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion. Viruses 2020, 12, 290.
Abstract
Purinergic receptors are inflammatory mediators activated by extracellular nucleotides released by dying or injured cells. Several studies have described an important role for these receptors in HIV-1 entry, particularly regarding their activity on HIV-1 viral membrane fusion. Several reports identify purinergic receptor antagonists that inhibit HIV-1 membrane fusion; these drugs are suspected to act through antagonizing Env-chemokine receptor interactions. They also appear to abrogate activity of downstream mediators that potentiate activation of the NLRP3 inflammasome pathway. Here we review the literature on purinergic receptors, the drugs that inhibit their function, and the evidence implicating these receptors in HIV-1 entry.
Keywords
fusion; purinergic; HIV-1; P2X1; P2X7
Subject
Biology and Life Sciences, Anatomy and Physiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
